{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:17Z","timestamp":1794360497762,"version":"4.9.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>\u0130ntroduction<\/jats:title>\n<jats:p>Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and\/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant\/intolareted to colchicine or complicated with amyloidosis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3\u2009months, and these data were analyzed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Forty-one (63.1%) patients used anakinra (100\u2009mg\/day) and 24 (36.9%) patients used canakinumab (150\u2009mg\/8\u2009week). The median duration of anti-IL-1 agents use was 7\u2009months (range, 3\u201330). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR)\u2009\u2265\u200960\u2009ml\/min\/m<jats:sup>2<\/jats:sup>, the median proteinuria decreased from 2390\u2009mg\/day (range, 1400\u20137200) to 890\u2009mg\/day (range, 120\u20132750) (<jats:italic>p<\/jats:italic>\u2009=\u20090.008). No serious infections were detected, except in one patient.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR\u2009\u2265\u200960\u2009ml\/min\/m<jats:sup>2<\/jats:sup>, but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the long-term effects of these treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s42358-020-0117-1","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T10:03:01Z","timestamp":1580378581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant\/unresponsive familial Mediterranean fever"],"prefix":"10.1186","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6953-4276","authenticated-orcid":false,"given":"Ali","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-8848","authenticated-orcid":false,"given":"Mehmet Emin","family":"Derin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-3896","authenticated-orcid":false,"given":"Fatih","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3624-4958","authenticated-orcid":false,"given":"Burak","family":"Karaka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-6498","authenticated-orcid":false,"given":"Yal\u00e7\u0131n","family":"Karag\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"1","key":"117_CR1","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.lpm.2018.08.014","volume":"48","author":"H Ozdogan","year":"2019","unstructured":"Ozdogan H, Ugurlu S. Familial Mediterranean fever. Presse Med. 2019;48(1):e61\u201376. https:\/\/doi.org\/10.1016\/j.lpm.2018.08.014.","journal-title":"Presse Med"},{"issue":"4 Suppl 34","key":"117_CR2","first-page":"S31","volume":"22","author":"F Onen","year":"2004","unstructured":"Onen F, Sumer H, Turkay S, Akyurek O, Tunca M, Ozdogan H. Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S31\u20133.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"117_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5152\/eurjrheum.2014.006","volume":"1","author":"I Sari","year":"2014","unstructured":"Sari I, Birlik M, Kasifoglu T. Familial Mediterranean fever: an updated review. Eur J Rheumatol. 2014;1(1):21\u201333. https:\/\/doi.org\/10.5152\/eurjrheum.2014.006.","journal-title":"Eur J Rheumatol"},{"key":"117_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.md.0000152370.84628.0c","volume":"84","author":"M Tunca","year":"2005","unstructured":"Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1\u201311.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"117_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40620-017-0426-6","volume":"31","author":"S Sethi","year":"2018","unstructured":"Sethi S, Theis JD. Pathology and diagnosis of renal non-AL amyloidosis. J Nephrol. 2018;31(3):343\u201350. https:\/\/doi.org\/10.1007\/s40620-017-0426-6.","journal-title":"J Nephrol"},{"issue":"2","key":"117_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.berh.2016.09.001","volume":"30","author":"A G\u00fcl","year":"2016","unstructured":"G\u00fcl A. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2016;30(2):296\u2013303. https:\/\/doi.org\/10.1016\/j.berh.2016.09.001.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"117_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208690.","journal-title":"Ann Rheum Dis"},{"key":"117_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","volume":"43","author":"V Hentgen","year":"2013","unstructured":"Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013;43:387\u201391.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"117_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acr.23446","volume":"70","author":"S Akar","year":"2018","unstructured":"Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I, C\u0131nar M, et al. Nationwide experience with off-label use of Interleukin-1 targeting treatment in familial Mediterranean fever patients. Arthritis Care Res. 2018;70(7):1090\u20134. https:\/\/doi.org\/10.1002\/acr.23446.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"117_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/14397595.2016.1194510","volume":"27","author":"O Kucuksahin","year":"2017","unstructured":"Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol. 2017;27(2):350\u20135. https:\/\/doi.org\/10.1080\/14397595.2016.1194510.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"117_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5152\/eurjrheum.2018.18036","volume":"5","author":"BM Kohler","year":"2018","unstructured":"Kohler BM, Lorenz H-M, Blank N. IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. Eur J Rheumatol. 2018;5(4):230\u20134. https:\/\/doi.org\/10.5152\/eurjrheum.2018.18036.","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"117_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00467-015-3249-5","volume":"31","author":"R Topaloglu","year":"2016","unstructured":"Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol. 2016;31(4):633\u201340.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"117_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10067-014-2772-2","volume":"35","author":"ZB \u00d6z\u00e7akar","year":"2016","unstructured":"\u00d6z\u00e7akar ZB, \u00d6zdel S, Y\u0131lmaz S, Kurt-\u015e\u00fck\u00fcr ED, Ekim M, Yal\u00e7\u0131nkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35(2):441\u20136.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"117_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14397595.2018.1457469","volume":"29","author":"\u00d6zkan Varan","year":"2018","unstructured":"Varan \u00d6., Kucuk H., Babaoglu H., Guven SC., Ozturk MA., Haznedaroglu, et al (2019). Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol, 29(2), 363\u2013366. https:\/\/doi.org\/10.1080\/14397595.2018.1457469.","journal-title":"Modern Rheumatology"},{"issue":"1","key":"117_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","volume":"12","author":"S Ugurlu","year":"2017","unstructured":"Ugurlu S, Hacioglu A, Adibnia Y, Hamuryudan V, Ozdogan H. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017;12(1):105. https:\/\/doi.org\/10.1186\/s13023-017-0642-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"117_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3109\/14397595.2016.1162261","volume":"26","author":"T Koga","year":"2016","unstructured":"Koga T, Migita K, Kawakami A. Biologic therapy in familial Mediterranean fever. Mod Rheumatol. 2016;26(5):637\u201341.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"117_CR17","doi-asserted-by":"publisher","first-page":"e1008038","DOI":"10.1371\/journal.pgen.1008038","volume":"15","author":"Z Li","year":"2019","unstructured":"Li Z, Akar S, Yarkan H, Lee SK, \u00c7etin P, Can G, et al. Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis. PLoS Genet. 2019;15(4):e1008038. https:\/\/doi.org\/10.1371\/journal.pgen.1008038.","journal-title":"PLoS Genet"},{"key":"117_CR18","first-page":"75","volume":"10","author":"JC van der Hilst","year":"2016","unstructured":"van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75\u201380.","journal-title":"Biologics"},{"issue":"8","key":"117_CR19","doi-asserted-by":"publisher","first-page":"e13345","DOI":"10.1111\/ctr.13345","volume":"32","author":"S Trabulus","year":"2018","unstructured":"Trabulus S, Korkmaz M, Kaya E, Seyahi N. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transpl. 2018;32(8):e13345. https:\/\/doi.org\/10.1111\/ctr.13345.","journal-title":"Clin Transpl"},{"issue":"12","key":"117_CR20","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","volume":"56","author":"T Youngstein","year":"2017","unstructured":"Youngstein T, Hoffmann P, G\u00fcl A, Lane T, Williams R, Rowczenio DM, et al. International multi-Centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology (Oxford, England). 2017;56(12):2102\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kex305.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"117_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5152\/eurjrheum.2017.16075","volume":"4","author":"U \u0130lgen","year":"2017","unstructured":"\u0130lgen U, K\u00fc\u00e7\u00fck\u015fahin O. Anakinra use during pregnancy: report of a case with familial Mediterranean fever and infertility. Eur J Rheumatol. 2017;4(1):66\u20137.","journal-title":"Eur J Rheumatol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-0117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-020-0117-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-0117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:33:38Z","timestamp":1611880418000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-020-0117-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1186\/s42358-020-0117-1","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"6 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The approval from the ethics committee of Cumhuriyet University Medical Faculty was obtained for this study with the decision no 2019\u201304\/29. The study was carried out in accordance with the World Medical Association\u2019s Declaration of Helsinki. Patients\u2019 informed consents were obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publish the manuscript in Advances in Rheumatology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}